1. Nogueira A, Pires MJ, Oliveira PA. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo. 2017; 31(1): 1-22. [
DOI:10.21873/invivo.11019] [
PMID] [
PMCID]
2. Clyne N, Hellberg M, Kouidi E, Deligiannis A, Höglund P. Relationship between declining glomerular filtration rate and measures of cardiac and vascular autonomic neuropathy. Nephrol. 2016. 21(12): [
DOI:10.1111/nep.12706] [
PMID]
3. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Ren Dis. 2017; 10: 35. [
DOI:10.2147/IJNRD.S101808] [
PMID] [
PMCID]
4. Boissier R, Sichez PC, Tran S, Delaporte V, Karsenty G, Lechevallier E. Comparison of glomerular filtration rate (GFR) loss after nephrectomy in 3 populations: Living donor nephrectomy, radical nephrectomy and partial nephrectomy for cancer. Eur Urol (Supplements). 2018; 17(2): e765. [
DOI:10.1016/S1569-9056(18)31364-2]
5. Shirazian S, Aina O, Park Y, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nep Ren Dis. 2017; 10: 11. [
DOI:10.2147/IJNRD.S108045] [
PMID] [
PMCID]
6. Webster AC, Nagler EV, Morton RL, Masson Ph. Chronic kidney disease. Lancet. 2017; 389(10075): 1238-1252. [
DOI:10.1016/S0140-6736(16)32064-5]
7. Pezeshgi A, Ghodrati S, Kiafar M, Kamali K, Asadi-Khiavi M. Study of neutrophil gelatinase-associated lipocalin in patients with cardiovascular shock. J Renal Inj Prev. 2018; 7(3): 144-147. [
DOI:10.15171/jrip.2018.36]
8. Ku E, Glidden DV, Johansen KL, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015; 87(5): 1055-1060. [
DOI:10.1038/ki.2014.376] [
PMID] [
PMCID]
9. Chan T-C, Zhang Z, Lin BCh, et al. Long-term exposure to ambient fine particulate matter and chronic kidney disease: a cohort study. Environ Health Perspect. 2018; 126(10): 107002. [
DOI:10.1289/EHP3304] [
PMID] [
PMCID]
10. Li PKT, Lui SL, Ng JKCh, et al. Addressing the burden of dialysis around the world: A summary of the roundtable discussion on dialysis economics at the first international congress of chinese nephrologists. Nephrol. 2017; 22: 3-8. [
DOI:10.1111/nep.13143] [
PMID]
11. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012; 81(5): 442-448. [
DOI:10.1038/ki.2011.379] [
PMID] [
PMCID]
12. Jha V, Garcia G, Iseki KSH, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260-272. [
DOI:10.1016/S0140-6736(13)60687-X]
13. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012; 380(9859): 2095-2128. [
DOI:10.1016/S0140-6736(12)61728-0]
14. Luyckx VA, Tonelli M, J.W.J.B.o.t.W.H.O. Stanifer. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6): 414. [
DOI:10.2471/BLT.17.206441] [
PMID] [
PMCID]
15. Saber A, Naghibzadeh Tahami A, Najafipour H, Azmandian J. Assessment of prevalence of chronic kidney disease and its predisposing factors in Kerman city. Nephro-Urology Monthly. 2017; 9(2): [
DOI:10.5812/numonthly.41794]
16. Nafar M, Mousavi SM, Mahdavi M, et al. Burden of chronic kidney disease in iran a screening program is of essential need. Iran J Kidney Dis. 2008; 2(4): 183-192.
17. De Nicola L, Minutolo RJKI. Worldwide growing epidemic of CKD: fact or fiction. Kidney Int. 2016; 90(3): 482-484. [
DOI:10.1016/j.kint.2016.05.001] [
PMID]
18. Levey AS, LAJAJoKD Inke. GFR as the "gold standard": estimated, measured, and true. Am J Kidney Dis. 2016; 67(1): 9-12. [
DOI:10.1053/j.ajkd.2015.09.014] [
PMID]
19. Alkandari O, Hebert D, Langlois V, Robinson L A, Parekh RS. Validation of serum creatinine-based formulae in pediatric renal transplant recipients. Pediatr Res. 2017; 82(6): 1000. [
DOI:10.1038/pr.2017.209] [
PMID]
20. Bretagne M, Jouinot A, Durand JP, et al. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chem Pharm. 2017; 80(1): 45-53. [
DOI:10.1007/s00280-017-3326-5] [
PMID]
21. Qiu X, Liu CH , Ye Y, et al. The diagnostic value of serum creatinine and cystatin c in evaluating glomerular filtration rate in patients with chronic kidney disease: a systematic literature review and meta-analysis. Oncotarget. 2017; 8(42): 72985. [
DOI:10.18632/oncotarget.20271]
22. Kirsch AH, Rosenkranz AR. Pre-chronic Kidney Disease (CKD)? Is It Time for a New Staging?, in Prehypertension and Cardiometabolic Syndrome. 2019; 231-240. [
DOI:10.1007/978-3-319-75310-2_16]
23. Antonucci E, Lippi G, Ticinesi A, et al. Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker for the early diagnosis of acute kidney injury (AKI). Acta Biomed. 2014; 85(3): 289-294.
24. Devarajan PJSJOC, investigation L. Neutrophil gelatinase‐associated lipocalin (NGAL): a new marker of kidney disease. Scan J Clin Lab Inv. 2008. 68: 89-94. [
DOI:10.1080/00365510802150158] [
PMID] [
PMCID]
25. Helanova K, Spinar J, Parenica J. Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) in patients with cardiovascular diseases-review. Kidney Blood Pres Res. 2014; 39(6): 623-629. [
DOI:10.1159/000368474] [
PMID]
26. Munilakshmi U, Shashidhar KN, Muninarayana C, Reddy M, Lakshmaiah V. Neutrophil gelatinase associated lipocalin (ngal), an early marker for urinary tract infection and acute kidney injury. Asian J Biochem. 2018; 13(1): 15-21. [
DOI:10.3923/ajb.2018.15.21]
27. Gharishvandi F, Kazerouni F, Rahimipour A, Nasiri M. Evaluation of some factors affecting the risk of kidney damage in patients with hypertension. Arch Adv Biosci. 2014; 5(4).
28. Gharishvandi F, Kazerouni F, Rahimipour A, Nasiri M. Comparative assessment of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin cas early biomarkers for early detection of renal failure in patients with hypertension. Iran Biomed J. 2015; 19(2): 76.
29. Basturk T, Sari O, Koc Y, et al. Prognostic significance of NGAL in early stage chronic kidney disease. Min Urol Nefrol. 2017; 69(3): 307-312.
30. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin cmeasured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47(1): 312-318. [
DOI:10.1038/ki.1995.40] [
PMID]
31. Martin MV, Barroso S, Herráez O, Sande FD, Caravaca F. Cystatin cas a renal function estimator in advanced chronic renal failure stages. Nefrología. 2006; 26(4): 433-438.
32. Pezeshgi A, Abedi Azar S, Ghasemi H, Kamali K, Esmaeilzadeh A. Role of plasma neutrophil gelatinase-associated lipocalin as an emerging biomarker of acute renal failure following kidney transplantation and its correlation with plasma creatinine. J Renal Inj Prev. 2016; 5(2): 98. [
DOI:10.15171/jrip.2016.21] [
PMID] [
PMCID]
33. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(2): 337-344. [
DOI:10.2215/CJN.03530708] [
PMID] [
PMCID]
34. Ghonemy TA, Amro GM. Plasma neutrophil gelatinase-associated lipocalin (NGAL) and plasma cystatin C (CysC) as biomarker of acute kidney injury after cardiac surgery. Saudi J Kidney Dis Transpl. 2014; 25(3): 582. [
DOI:10.4103/1319-2442.132194] [
PMID]
35. Mitsnefes MM, Kathman TS, Mishra J, et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Kidney Blood Pre Res. 2007; 22(1): 101. [
DOI:10.1007/s00467-006-0244-x] [
PMID]
36. Fisher MA, Taylor GWJJOP. A prediction model for chronic kidney disease includes periodontal disease. J Periodontol. 2009; 80(1): 16-23. [
DOI:10.1902/jop.2009.080226] [
PMID] [
PMCID]